熱門資訊> 正文
Ionis Pharmaceuticals表示，Donidalorsen在遗传性血管性水肿患者中的3期OASISplus前瞻性转换研究的结果发表在《过敏与临床免疫学实践》杂志上
2025-07-21 19:05
- Results indicate that patients who switched to donidalorsen from prior prophylactic treatments showed a 62% further reduction in mean monthly HAE attack rate from baseline, and 84% of patients surveyed reported preference for donidalorsen.
- Patients switched to donidalorsen without increased breakthrough attacks and experienced further reductions in mean attack rate from baseline.
- Donidalorsen is currently under review with the U.S. FDA as a potential first-in-class prophylactic treatment for HAE; PDUFA date August 21
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
